As of today (2022-08-10), Illumina's share price is $227.30. Illumina's Tangible Book per Share of Mar. 2022 for the quarter that ended in Mar. 2022 was $3.65. Hence, Illumina's Price to Tangible Book Ratio of today is 62.31.
The historical rank and industry rank for Illumina's Price-to-Tangible-Book or its related term are showing as below:
ILMN'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17 Med: 12.83 Max: 461.34
Current: 62.27
During the past 13 years, Illumina's highest Price to Tangible Book Ratio was 461.34. The lowest was 1.17. And the median was 12.83.
ILMN's Price-to-Tangible-Book is ranked worse than 97.34% of 188
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.30
vs ILMN: 62.27
A closely related ratio is called PB Ratio. As of today, Illumina's share price is $227.30. Illumina's Book Value per Sharefor the quarter that ended in Mar. 2022 was $69.36. Hence, Illumina's P/B Ratio of today is 3.28.
Illumina Price-to-Tangible-Book Historical Data
The historical data trend for Illumina's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Tangible-Book
17.81
16.08
13.38
14.78
158.45
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Price-to-Tangible-Book
14.41
17.17
442.32
158.45
95.78
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Price-to-Tangible-Book Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Illumina's Price-to-Tangible-Book falls into.
Illumina Price-to-Tangible-Book Calculation
Illumina's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Illumina Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Illumina's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
12.5(5.82%) Volume: 1,001,148 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
